Lasmiditan - CoLucid Pharmaceuticals

Drug Profile

Lasmiditan - CoLucid Pharmaceuticals

Alternative Names: COL-144; LY-573144

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; Lundbeck A/S
  • Developer CoLucid Pharmaceuticals
  • Class Antimigraines; Benzamides; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Serotonin 1F receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 22 Nov 2017 Eli Lilly completes a phase I drug interaction trial in healthy volunteers in USA (NCT03270644)
  • 17 Oct 2017 Eli Lilly initiates enrolment in a phase I trial in Healthy volunteers in USA (PO) (NCT03310411)
  • 16 Oct 2017 Eli Lilly initiates enrolment in a phase I trial in Healthy volunteers in USA (PO) (NCT03308669)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top